Six different substitution mutations were identified in four different amino acid residues of antithrombin strand 1C and the polypeptide leading into strand 4B (F402S, F402C, F402L, A404T, N405K, and P407T), and are responsible for functional antithrombin deficiency in seven independently ascertained kindreds (Rosny, Torino, Maisons-Laffitte, Paris 3, La Rochelle, Budapest 5, and Oslo) affected by venous thromboembolic disease. In all seven families, variant antithrombins with heparin-binding abnormalities were detected by crossed immunoelectrophoresis, and in six of the kindreds there was a reduced antigen concentration of plasma antithrombin. Two of the variant antithrombins, Rosny and Torino, were purified by heparin-Sepharose and immunoaffinity chromatography, and shown to have greatly reduced heparin cofactor and progressive inhibitor activities in vitro. The defective interactions of these mutants with thrombin may result from proximity of s1C to the reactive site, while reduced circulating levels may be related to siC proximity to highly conserved internal ft strands, which contain elements proposed to influence serpin turnover and intracellular degradation. In contrast, siC is spatially distant to the positively charged surface which forms the heparin binding site of antithrombin; altered heparin binding properties of siC variants may therefore reflect conformational linkage between the reactive site and heparin binding regions of the molecule. This work demonstrates that point mutations in and immediately adjacent to strand 1C have multiple, or pleiotropic, effects on this serpin, leading ultimately to failure of its regulatory function. (J.
Introduction
Antithrombin is a member of the serine proteinase inhibitor (serpin) superfamily ( 1 ). Its main function is the regulation of blood coagulation proteinases, such as thrombin, that are generated during coagulation activation (2) (3) (4) . Antithrombin has two distinct functional domains: one (the reactive site) interacts with the proteinase, and the other binds to heparin. Mainte-nance of an adequate level, > 70%, of functional antithrombin activity in blood is essential to ensure effective inhibition of coagulation proteinases: inheritance of genetic defects that lower the absolute amount of antithrombin (type I), or that produce inactive (variant) forms ofthe inhibitor (type II), predispose to familial thrombotic disorders (5, 6) .
Numerous variants ofantithrombin have now been characterized at the molecular level (7) . Mutations that alter the reactive site (types Ha and HIb) are generally located near the COOH terminus of the molecule, while heparin binding defects (type IIc) (classification according to Sas et al. [8, 9 ] ) are usually caused by single amino acid substitutions near the NH2 terminus.
We have studied seven different families in which the propositi suffered thromboembolic disorders and were found to have reduced levels of functional antithrombin. We show here that variant proteins are produced in each case and we identify the genetic abnormalities responsible for the altered functional properties ofthe antithrombins. Amongst these seven families, there are six different point mutations leading to single amino acid substitutions in the 402-407 region of the antithrombin protein. These substitutions have pleiotropic (multiple) effects; they alter the reactive site and heparin-binding properties ofthe variant antithrombins, and decrease their circulating levels in most cases.
Methods

Family histories
The descriptions of the family histories that follow should be considered together with the antithrombin assay results summarized in Table I.
Case I An 18-yr-old male from the town of Rosny, France, was referred for investigation in August 1989, because of a history of deep vein thrombosis (DVT).' At the age of 15 yr, he developed a spontaneous superficial vein thrombosis of the right leg. 2 yr later, he had a DVT (diagnosed by venography), 7 d after appendectomy. He was treated with heparin, followed by oral anticoagulants for a period of 7 mo. Repeated echo-Doppler studies showed persistence of obstruction of the left superficial femoral and iliac veins. Antithrombin deficiency was diagnosed on the basis of reduced levels of activity and antigen in plasma, with the former being consistently lower than the latter (activity 52%, antigen 70%).
His mother, aged 37 yr, originating from Gabon, also has antithrombin deficiency (activity 46%, antigen 60%). She had a clinically diagnosed left calf vein thrombosis at the age of 26 yr, while receiving estroprogestogen. It should be noted that she has had three pregnancies without prophylactic anticoagulant treatment (one before and two after the thrombosis) and that she also received estroprogestogen after her second pregnancy: no other episodes of thrombosis were observed. The propositus has no contact with his father who could not therefore be examined.
Case 2
A 16-yr-old male from Torino, Italy, was referred for investigation after a DVT of the right leg. Possible predisposing events were repeated trauma of the same leg 1 wk and 1 mo before. The thrombosis was confirmed by echo-Doppler and computerized tomography: popliteal, superficial femoral, and iliac veins were occluded. He was treated first with urokinase together with heparin. Levels of antithrombin were determined to be low (activity 46%, antigen 69%) and were taken to indicate increased consumption; consequently, he received antithrombin concentrates ( 1,000 U on day 2; 2,000 U on day 3; 3,000 U from day 5-10). Warfarin was started on day 10 and heparin stopped on day 13. Oral anticoagulants were continued for 6 mo. Echo-Doppler performed at 4 mo showed a thrombosis up to the iliac vein and a collateral circulation by the internal saphenous vein. Antithrombin levels in his parents and his sister were normal and there was no family history of thrombosis.
Case 3
This involves an affected man (activity 56%, antigen 73%) from Maisons-Laffitte, France, with only one episode ofleft calfvein thrombosis at the age of 55 yr. He was referred for familial thromboembolic antecedents: his sister, aged 40 yr, developed a left ilio-femoral venous thrombosis with pulmonary embolism at the age of 28 yr, after a knee ligamentoplasty performed without interruption of estroprogestative pill. She was treated with oral anticoagulants for 2 yr without a further episode of thrombosis. At the age of 30 yr, she received prophylactic anticoagulant treatment for 2 yr after knee surgery. Despite her thrombosis, her antithrombin levels in plasma appear to be normal (activity 105%, antigen 104%).
An affected (antithrombin activity 55%, antigen 75%) son of the propositus, 32 yr old, developed a spontaneous left ilio-femoral thrombosis at the age of 17 yr. He was treated with heparin followed by oral anticoagulants for 2 yr. 10 yr later he developed a spontaneous ilio-femoral thrombosis and for the last 3 yr has been treated with acenocoumarol, without recurrence of thrombotic episodes.
Two other sons, 26 and 18 yr old, have no history ofthrombosis and their antithrombin levels are normal. A 25-yr-old unaffected (i.e., with normal antithrombin levels) nephew (son of an unaffected brother), however, presented with a left calfvein thrombosis after appendectomy at the age of 17 yr. After 1 yr of treatment on acenocoumarol, this was discontinued and he has been free of recurrences for 3 yr.
The occurrence of thrombosis in this third family, often present in association with normal antithrombin levels, suggests a second independent abnomality, the nature of which is presently unknown.
Case 4
The propositus of the antithrombin Paris 3 kindred is a 41-yr-old male (antithrombin activity 48%, antigen 72%). At the age of 20 yr he had a fracture of the right malleolus which required a plaster cast for 40 ds: calf oedema followed cast removal. At the age of 35 yr, surgery was planned for inguinal hernia and, as his mother and two sisters were also known to be antithrombin deficient (Table I) , he was examined for thrombosis by echo-Doppler: signs of previous right femoro-popliteal thrombosis were found. At the age of 39 yr, he experienced superficial thrombosis which was treated with a low molecular weight heparin. After another thrombotic episode, echo-Doppler demonstrated sequelae of right and left side DVT. Consequently, he has been put on long-term oral anticoagulants.
One affected sister (antithrombin activity 60%, antigen 78%), aged 44 yr, has had repeated DVT and pulmonary embolism after deliveries and an induced abortion. A second affected sister (activity 54%, antigen 70%), aged 51 yr has had no thrombosis, despite having three children. One ofthese children is antithrombin deficient (activity 58%, antigen 65%) and has had a DVT. Furthermore, the mother of the propositus, 71 yr, had postpartum superficial thrombosis at 17 yr, followed by a second thrombosis during the next pregnancy. At 62 yr she experienced ilio-femoral thrombosis, which was treated with long-term oral anticoagulants.
Case 5
The propositus (antithrombin activity 55%, antigen 73%) of the antithrombin La Rochelle kindred had repeated sprains between the ages of 17 and 28 yr, the last one being associated with pain and oedema. Diagnosis of DVT was suggested for the first time when he was 28 yr, after leg pain. Repeated episodes of dyspnoea culminated in investigation by venography, which revealed a previous left and recent right thrombosis. He received heparin, and during treatment a pulmonary embolism was confirmed by lung scan. Urokinase/plasminogen treatment was given and a vena caval interruption was performed. For the last 14 yr, he has been given oral anticoagulants.
His mother, who also has reduced antithrombin levels (activity 55%, antigen 54%), is now 67 yr old and experienced no thrombotic problems following an appendectomy at 18 yr and her first three pregnancies. She experienced a left DVT after the fourth delivery and has had repeated episodes of superficial thrombophlebitis. She is not treated with long-term oral anticoagulants.
His sister (antithrombin activity 56%, antigen 60%), aged 44 yr, developed a left calf DVT at 22 yr: thrombosis was associated with prolonged bed rest after influenza. She was treated with heparin for 48 h and oral anticoagulants were begun, but the DVT extended up the thigh and into the pelvis. Heparin was given again and after a move to oral anticoagulants she developed a DVT of the right leg. Additional episodes of DVT were investigated by venography, which revealed extensive thrombosis of the right femoral, external, and common iliac veins. Recurrency of thrombosis after stopping anticoagulants has lead to oral anticoagulation for the past 20 yr.
Case 6
This involves a family from Budapest, Hungary, with an extensive pedigree and a history ofsevere thrombotic episodes. A combination of at least two defects (antithrombin and protein C deficiencies), which apparently segregate separately, can explain the severe thrombosis. A comprehensive report of the family history has appeared elsewhere (10) . While only the propositus was investigated in the present study (antithrombin activity 70%, antigen 100%), it is instructive to review briefly the family history. Of 10 brothers and 2 sisters, at least 2 siblings died ofpulmonary embolism at an early age (21 and 16 yr). Two other children died without definite (autopsy) diagnosis. Four other family members with functional antithrombin deficiency suffered from severe thromboembolism at 15, 19, 23, and 46 yr and survived. Three family members (the grandmother and two brothers) with functional antithrombin deficiency have not developed thrombosis. Available antithrombin levels, including those reported elsewhere ( 10) , are listed in Table I .
Case 7
Case 7 involves an antithrombin deficient kindred from Oslo, Norway. Details of the family history are contained in a report ( 11 ) that was the first to recognize an association between inherited antithrombin deficiency and venous thrombosis. More recently, Hultin et al. ( 12) analyzed plasma from members of this family by crossed immunoelectrophoresis (CIE) in the presence of heparin and observed a cathodal variant protein in affected individuals. While the inheritance of antithrombin deficiency and its association with thrombosis is well documented in this family, a brief updated summary is required. The propositus (antithrombin activity 50%, antigen 48%) has had several, severe thromboses involving obstruction of the mesenteric veins, necessitating removal of much of his small bowel. Of 25 family members investigated, 12 were found to have functional antithrombin deficiency (see Table I ). Eight of these individuals have had DVT, and in seven this was recurrent. The mean age of onset of the first DVT was 19 yr of age.
Protein investigations
Assays of antithrombin levels in plasma were performed by antigen and functional methods. Antigen levels of cases 1-6 were measured using Nor Partigen plates (Behringwerke, Marburg, FRG) or a nephelometric method (Nephelometric Analyzer, Behringwerke), while the functional assay employed a heparin cofactor method using either S 2222 (KabiVitrum, Uxbridge, UK), or Dupont reagents and an ACA SX Instrument. Functional and immunological antithrombin levels for case 7 were determined as previously described ( 1 1, 13, 14) .
CIE was performed with heparin in the first dimension (9, 15), as described ( 12, 16) . The polyclonal antibodies were purchased from DakoPatts (High Wycombe, UK) and Behringwerke.
Normal pooled plasma was prepared by centrifugation of citrated blood from healthy laboratory staff. Citrated plasma was also prepared from the propositi, all of whom are shown to be heterozygous for variant antithrombins (hereafter termed antithrombins Rosny, Torino, Maisons-Laffitte, Paris 3, La Rochelle, Budapest 5, and Oslo). Antithrombin was isolated from normal plasma and from the propositi with antithrombins Rosny and Torino (insufficient plasma was available from the other families) by chromatography on heparin-Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden) (16, 17) . Plasma (-30 ml) was applied to the column in 0.1 M Tris-HCl, pH 7.4, containing 0.4 M NaCl: plasma with antithrombin Rosny was subject to a preliminary precipitation step with dextran sulphate. Under the conditions used, approximately half of the antithrombin in each case did not bind to the column and was recovered in the breakthrough fraction containing most of the plasma; when the same quantity of normal plasma was applied to the same column, minimal amounts (barely detectable) of antithrombin did not bind. The breakthrough fractions from the patients' plasmas were separately pooled. The abilities of the two pools to form thrombin-antithrombin complex were studied using an immunoassay (see below). The variant antithrombins were then isolated from these pooled fractions by immuno-affinity chromatography on immobilized polyclonal antibody (DakoPatts) to normal antithrombin ( 18 ) . The samples were applied to the column in SDS PAGE and immunoblotting were performed under nonreducing conditions using 10-15% Phast Gels (Pharmacia) and rabbit antiantithrombin polyclonal antibody (DakoPatts), as described (21 ) .
The reaction of purified antithrombin (normal antithrombin and antithrombins Rosny and Torino) with thrombin was studied at 37°C in the absence of heparin. Purified human thrombin (20 nM) was incubated with various concentrations ofantithrombins (see Fig. 5 ) in 0. 15 M NaCl, 0.05 M Tris-HCI, pH 7.4, containing 0.1% polyethylene glycol 6,000 (18, 22) . At different times, subsamples were withdrawn and added to cuvettes containing the chromogenic substrate S2238 (KabiVitrum) to determine residual thrombin activity. Relative velocity, V/V., where Vo is the initial velocity, of substrate hydrolysis was plotted against time.
DNA amplification and direct sequencing Genomic DNA was isolated from peripheral blood leukocytes of each ofthe subjects investigated. For all cases, the polymerase chain reaction (PCR) was used to amplify specifically segments of the antithrombin gene that encode the seven exons and flanking intron sequences. Oligonucleotide primers and thermal cycling conditions have been described previously (23) (24) (25) . One of a pair of amplification primers was 5'-biopH 6.9 (19) , after extensive washing with the application buffer. Normal antithrombin was also isolated from plasma using this column. For kinetic studies, the antithrombins (normal and variant) were subjected to an additional purification step on ion exchange chromatography, to remove any contaminating heparin from the heparin-Sepharose step (20) .
The abilities of the variant antithrombins (Rosny and Torino) in pooled breakthrough fractions to form thrombin-antithrombin complex were compared to that of antithrombin in normal plasma using a commercial assay (Enzygnost-TAT; Behringwerke). Samples were diluted to give a final antithrombin concentration (determined by Nor Partigen plates) of 5.38 nM 
Results
Antithrombin activity levels were decreased in all cases and, with the exception ofantithrombin Budapest 5, this was accompanied by a reduction in antithrombin antigen levels (Table I) . Antigen levels were not, however, reduced in proportion to functional activity levels for six out ofseven cases in this series, suggesting the possibility of dysfunctional variant proteins. Plasma samples from all seven families were subjected to CIE with heparin in the first dimension to investigate this possibility (Fig. 1 ) (31 ) .
Antithrombins Rosny and Torino were isolated using hepa-rin-Sepharose chromatography as a preliminary step. Plasma samples were applied in 0.4 M NaCi and the majority of their slow moving components did not bind to the column, Fig. 2 . The ability ofthese variant antithrombin fractions to inactivate thrombin was studied using a thrombin-antithrombin complex immunoassay. As can be seen in Fig. 3 , the variant antithrombins from both patients did not form thrombin-antithrombin complexes, either in the absence or presence ofhepann. The variants were further purified from the heparin-Sepharose column breakthrough fractions by application to and elution from an anti-antithrombin-Sepharose column. They were A TAT formation in the absence of heparin AT Rosny, antithrombin Rosny purified using heparin-Sepharose chromatography followed by the anti-antithrombin chromatography; AT Torino, antithrombin Torino purified by heparin-Sepharose chromatography followed by anti-antithrombin chromatography. Time (mins) contaminated by several high molecular weight proteins, visualized after SDS PAGE, Fig. 4 . On immunoblotting the only band of antithrombin Rosny had the same mobility as normal antithrombin. In the case of antithrombin Torino, an additional diffuse high molecular weight component reacted with sT formation in the presence of heparin the antibody: its identity could not be ascertained. of the antithrombin gene was used to confirm the sequencing results of the family members, and to show that the mutation was not present in the panel of 50 normal subjects. It is probable that the mutation in antithrombin Torino was de novo, since the single base substitution was not present in either of the parents of the propositus. Using a panel of DNA probes, each specific for a hypervariable region and with a high heterozygosity, we showed that the genetic relationships have been correctly assigned.
The nucleotide substitution 402 TTC to TTA was identified in the mutant allele producing antithrombin Maisons-Laf- fitte, resulting in 402 Phe to Leu. This latter mutation creates a Dral cutting site; Dral restriction analysis was used to confirm the presence of the mutation in one antithrombin allele of the propositus and the one son who had reduced antithrombin assay results, Table I . The mutation was absent in the other kindred members and in 50 normal individuals.
Beparin binding site defects 7 Ile(ATC)-eAsn(AAC) [1] 24 Arg(CGC)-+Cys(TGC) [1] 41 Pro(CCG) Leu(CTG) [11] 47 Arg(CGT)-*oCys(TGT) [14] 47 Arg(CGT)-+His(CAT) [11] 47 Arg(CGT)-+Ser(AGT) [1] 99 Leu(CTC)-4Phe(CTT) [2] 129 Arg(CGA)-+Gln(CAA) [3] [1] 402 Phe(TTC)-+Ser(TCC) [1] 402 Phe(TTC)-+Leu(TTA) [1] 404 Ala(GCC)-+Thr(ACC) [2] 405 Asn(AAC)-+Lys(AAG) [1] 406 Arg(AGG)-*Met(ATG) [1] 407 Pro(CCT)-+Leu(CTT) [1] 407 Pro(CCT)-*Thr(ACT) [1] 429 Pro(CCT)-+Leu(CTT) [1] L _ _ II_ I~~~~~. ..
-']-'----
Reactive site defects 382 Ala(GCA)-*Thr(ACA) [3] 384 Ala(GCA)-+Ser(TCA) [4] 384 Ala(GCA)-+Pro(CCA) [5] 392 Gly(GGC)-+Asp(GAC) [1] 393 Arg(CGT)-4Cys(TGT) [3] 393 Arg(CGT)-*His(CAT) [4] 393 Arg(CGT)-4Pro(CCT) [1] 394 Ser(TCG)-+Leu(TTG) [2] Figure 7 . Summary of mutations resulting in the production of naturally occurring variant forms ofantithrombin. Many ofthese mutations are contained in the compilation database (7) , which also gives an account of their known frequency of recurrence (shown here in parentheses). This database also lists additional mutations that have not yet been reported fully. Note that the 429 Pro to Leu substitution is grouped with cases having pleiotropic effects. Proline-429 is adjacent to the 402-407 region ofthe tertiary structure (see Fig. 9 ) and also has pleiotropic effects upon the function of antithrombin (22) . The remaining families had mutations in the codons for amino acid residues 404, 405, and 407. Antithrombins Panis 3 and Oslo had mutations in codon 404 QCC to ACC, Ala to Thr. The antithrombin Oslo gene segregated with the S allele of the 5'-end length polymorphism, the (+) allele for the exon Fig. 7 ). Substitution ofPI residue 393 Arg by Cys, His, and Pro, and P2 residue 392 Gly by Asp, all completely block the inhibitor-proteinase reaction (20, (34) (35) (36) (37) (38) (39) . Substitution of P1' residue 394 Ser by Leu (40, 41) drastically impairs the function of the reactive site when thrombin is the target proteinase, but has less effect upon inhibitory function against Factor Xa (42) . Substitution of PlO0 and P12 residues, 384 Ala and 382 Ala, respectively (38, 43, 44) , causes the inhibitory reaction to be transformed into a substrate reaction in which the reactive bond is completely cleaved by the proteinase (23, 45, 46) . Substrate reactions have also been demonstrated for other serpins that have amino acid substitutions or insertions in the P1I2-PlO region (47, 48) .
Heparin binding to antithrombin is demonstrably altered by some amino acid substitutions. An antithrombin heparin binding site has been proposed on the basis of genetic data (18, (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) , together with information from chemical modification experiments (59) (60) (61) and the properties of the glycosylation isoform, antithrombin-f3 (62, 63) . It consists of a surface ofhigh positive charge density around helix D and the NH2-terminal sequence of antithrombin which is not present on other serpins. Some of the variant antithrombins with altered heparim binding properties have amino acid substitutions that directly affect basic amino acids (e.g., 24 Arg, 47 Arg, 129 Arg), while others have those that are thought to alter the conformation of the binding domain (e.g., 41 Pro, 99 Leu).
The variant forms of antithrombin considered above have been described as having "simple" phenotypes, characterized by defective thrombin interactions in the presence of normal heparin binding, or normal thrombin inhibition in the presence ofdefective heparin binding. Furthermore, the circulating concentrations ofthe proteins encoded by the normal and variant alleles in the heterozygous patients are usually similar, and the plasma antithrombin antigen concentration is near normal. In contrast, a total of eight different substitution mutants leading to antithrombin deficiency have now been identified in five positions of the 402-407 region (this report; [31, 64] ), see Fig. 7 , and these exhibit pleiotropic defects. Fig. 8 shows a sequence alignment for COOH-terminal "activation peptides" of antithrombin, a1-antitrysin, and ovalbumin. In the primary structure of antithrombin, the 402-407 region is located between the P1 residue of the reactive centre and highly conserved regions in strands 4B and 5B of the "activation peptide." The crystal structure of intact ovalbumin (65) can serve as a working prototype for the three dimensional structures of native (reactive loop intact) serpins, Fig. 9 . Antithrombin residues 402-407 map to strand IC and the polypeptide leading into strand 4B. The positions ofthe reactive site, heparin-binding site, and conserved elements ofthe "activation peptide" are marked in Fig. 9 , and the functional consequences ofthe 402-407 mutations will be considered in terms of this model.
In vitro studies of purified antithrombins Rosny and Torino (Fig. 5 ) and antithrombin Utah in plasma (31) revealed defective interactions with thrombin. Based on their presence in patients with clinical thrombosis, it is likely that the other 402-407 region variants also have abnormal interactions with thrombin. The P1 residue of antithrombin, 393 Arg, is the primary determinant of thrombin target specificity and interacts with the enzyme active site. However, because antithrombin inhibits thrombin more efficiently than several other serpins that also have arginine P1 residues (a2-antiplasmin, PAI-1, PAI-2, C1 inhibitor, and protein C inhibitor), it can be inferred that an extended inhibitor-enzyme contact surface surrounding the P1 residue participates in the recognition and inhibition of target enzymes by serpins. Inspection of Fig. 9 shows that the 402-407 region is in close proximity to the reactive loop containing the P1 residue, and may constitute part of the extended contact surface or be very close to it. Thus, based on their location near the P1 residue, mutations in the 402-407 region may block antithrombin-protease interactions directly or indirectly.
Heparin binding abnormalities have been demonstrated in seven 402-407 region variants by CIE of plasma (Fig. 1) . Decreased heparin affinity was confirmed for antithrombins Rosny and Torino by heparin-Sepharose chromatography (Fig. 2 ) , but not for antithrombin Utah ( 31 ) . Elements of the heparin-binding site are found on the lower face of the molecule shown in Fig. 9 . The heparin-binding site is distinct from the reactive site and the region containing 402-407 (upper part of the molecule shown), and spatially removed from them. Therefore, barring overall denaturation ofthe variants, the presence of heparin binding abnormalities in these mutants suggests that the reactive site end of antithrombin (containing the 402-407 region) is linked conformationally to the heparinbinding site at the other side of the molecule. The converse of this idea is the basis of conformation-based hypotheses to explain antithrombin heparin cofactor activity (3, 4) . The 402-407 substitutions map to strand IC and the polypeptide leading into s4B, and constitute a significant part of the interface between the C sheet at the reactive site pole of the inhibitor, and the internal B sheet which connects at its other end to alpha helices, forming the heparin-binding site of antithrombin (Fig.  9 B) . Thus, mutations in the 402-407 region may relay structural changes to the distal heparin binding site by perturbing the B sheet and the core of the molecule. In the extreme, it is possible that inducing perturbations in the core may disrupt protein folding and lead to a phenomenon of general protein denaturation, which would also be associated with a phenotype of defective target enzyme and cofactor interactions and decreased plasma levels.
Decreased circulating concentrations of several 402-407 region variants have been detected by CIE (Fig. 1) and Western blotting (31) and it had been suggested that integrity of this region is necessary for obtaining normal circulating serpin levels (66, 67) . Quantitative deficiencies of antithrombin 402-407 variants could be caused by decreased synthesis, increased intracellular degradation, impaired secretion, and/or increased turnover. Two highly conserved elements ofthe activation peptide map near to 402-407 in the tertiary structure and are thought to play important roles in regulating serpin intracellular degradation and turnover. Brodbeck and Brown noted that COOH-terminal frameshift mutations caused secretory defects in naturally occurring a,-antitrypsin mutants and used an in vitro mutagenesis approach to show that truncations before invariant proline-391 (marked with an asterisk in Fig. 9 ) are associated with intracellular degradation and prevent movement of the protein from the endoplasmatic reticulum to the Golgi apparatus (68) . Thus, intracellular degradation and decreased secretion may occur for some ofthe antithrombin 402-407 variants as a consequence of structural perturbations extending from the immediate vicinity ofthe substitutions to the region of the invariant proline (residue 391 in a1-antitrypsin).
Alternatively, accelerated turnover may be the mechanism responsible for quantitative deficiencies of some 402-407 variants in which structural abnormalities caused by the substitu- Figure 9 . Ovalbumin model (65) for intact serpin structure showing locations of antithrombin 402-407 substitution mutations relative to the reactive loop, the heparin-binding site, and the highly conserved regions of the activation peptide. Several discontinuities present in the polypeptide backbone are caused by low electron density in these portions of the crystal structure. Structural elements of interest are shown in the top view. The reactive loop is on the left and drawn in green. Strand IC and the polypeptide leading into strand 4B are blue. Side chains of the ovalbumin residues corresponding to substituted residues of antithrombin 402 and 403-407 variants are shown in ball and stick rendering. Side chains of invariant and highly conserved residues in strands 4B and 5B (yellow) of the activation peptide are red. The main chain of residue corresponding to invariant glycine 386 (a1-antitrypsin) is also red. The proposed ligand for the serpin-enzyme complex receptor (67) is located in strand 4B and is rendered in cylindrical format. Ovalbumin residues corresponding to antithrombin residues assigned to the heparin-binding site by chemical modification, genetic variant, and glycosylation isoform evidence are orange. The asterisk marks the invariant proline of ovalbumin that corresponds to proline-429 of antithrombin (altered in antithrombin Budapest (22)), and to proline-39 1 of a,-antitrypsin (required for normal secretion in vitro [69] ). The bottom view shows structural elements introduced in the top view in the context of the entire molecule.
Beta-sheets A, B, and C are drawn in green, yellow, and blue, respectively. tions lead to exposure of a highly conserved neoepitope (Fig.  9 ), proposed to serve as a ligand for hepatic serpin-enzyme complex receptors (67) . It is notable that the quantitative deficiency phenotype ofa,-antitrypsin Heerlen (69), which carries a leucine for proline substitution at the residue (369) corresponding to antithrombin 407 (see Fig. 8 ), suggests that this region of serpins is generally involved in determining circulating protein level.
In summary, the pleiotropic effects of antithrombin 402-407 substitution mutants can be rationalized in terms of a three-dimensional model derived from the crystal structure of native ovalbumin. The strand IC region containing the 402-407 mutations is contiguous with the reactive site and two highly conserved elements of the activation peptide that may play important roles in regulating serpin intracellular degradation and plasma clearance; this may explain defective interactions of slC mutants with thrombin, and their low circulating levels. In contrast, slC is distal to the positively charged surface which forms the heparin binding site of heparin; altered heparin-binding properties ofthe slC variants may therefore reflect conformational linkage between the reactive site and heparinbinding regions of the molecule. Alternatively, integrity of the 402-407 region may be required for antithrombin to fold correctly, and the pleiotropic effects of slC substitutions may represent the consequences of general protein denaturation. Finally, it is interesting that the antithrombin Budapest variant (22) exhibits pleiotropic reactive site and heparin-binding site defects, and carries a substitution (P429L) that maps near the 402-407 region in the tertiary structure (Fig. 9) , but not the primary structure.
